Ultrasound-Guided Extracorporeal Shock Wave Therapy for Calcific Tendinitis (ESWT)
Effectiveness of Ultrasound-Guided Extracorporeal Shock Wave Therapy for Calcific Tendinitis of the Shoulder: A Randomized Double-Blind Controlled Trial
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Shih-Wei Huang, MD
- Telefoonnummer: +886970747556
- E-mail: shihwei@tmu.edu.tw
Studie Locaties
-
-
Taipei
-
Taipei, Taipei, Taiwan, 116
- Werving
- Wan Fang Hospital, Taipei Medical University
-
Contact:
- Shih-Wei Huang
- Telefoonnummer: 0970747556
- E-mail: shihwei@tmu.edu.tw
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age between 20 and 70 years
- Unilateral calcific tendinitis of the shoulder confirmed by clinical physical examination, including a positive Neer's impingement test
- Symptom duration of more than 3 months
- Imaging (radiography and/or high-resolution ultrasound) demonstrating a calcific deposit within a rotator cuff tendon with a maximal diameter greater than 5 mm
- Baseline self-reported pain intensity greater than 4 on the Visual Analog Scale (VAS, 0-10)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Concomitant full-thickness rotator cuff tear
- History of fracture or surgery involving the ipsilateral shoulder
- Coagulopathy, or anticoagulant therapy that cannot be safely discontinued
- Pregnancy or breastfeeding
- Malignancy, particularly involving or adjacent to the shoulder region
- Local infection or skin lesion at the intended treatment site
- Injection therapy to the ipsilateral shoulder within the preceding 6 weeks
- Any other condition that, in the judgment of the investigator, makes the participant unsuitable for participation in the trial
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Ultrasound localization ESWT
Ultrasound image guided the depth and location of calcification point, Perform ESWT for calcific tendonitis of shoulder
|
Use ultrasound guided localization of calcific tendonitis of shoulder and then perform Extracorporeal Shock Wave Therapy, ESWT 0.12 to 0.25 mJ/mm 6000 times
|
|
Actieve vergelijker: Palpation localization ESWT
Palpation and depends the feedback of participants localization of ESWT points
|
Use palpation localization of calcific tendonitis of shoulder and then perform Extracorporeal Shock Wave Therapy, ESWT 0.12 to 0.25 mJ/mm 6000 times
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Constant-Murley Score (CMS)
Tijdsspanne: Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
The Constant-Murley Score is a clinician-administered instrument assessing shoulder function across four domains: pain (15 points), activities of daily living (20 points), range of motion (40 points), and strength (25 points), for a total score of 0-100.
Higher scores indicate better shoulder function.
The measure compares real-time high-resolution ultrasound-guided focused ESWT (experimental) with X-ray plus palpation-guided focused ESWT (control) for calcific tendinitis of the shoulder.
Assessed at baseline, Week 4, and Week 12; change from baseline is reported.
|
Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
|
Change in Pain Visual Analog Scale (VAS)
Tijdsspanne: Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
Pain intensity is self-reported on a 0-10 Visual Analog Scale, where 0 = no pain and 10 = worst imaginable pain.
Ratings are collected for pain at rest, pain with activity, night pain, and average pain over the past week.
Higher scores indicate greater pain.
Change from baseline is compared between the ultrasound-guided ESWT and landmark (X-ray + palpation)-guided ESWT groups.
Assessed at baseline, Week 4, and Week 12.
|
Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
|
Change from Baseline in Shoulder Pain and Disability Index (SPADI)
Tijdsspanne: Baseline, Week 4, Week 12
|
Patient-reported questionnaire comprising a 5-item pain subscale and an 8-item disability subscale, each item scored 0-10.
Subscale and total scores are expressed as percentages (0-100%), with higher scores indicating greater pain and disability.
|
Baseline, Week 4, Week 12
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Calcific Deposit Resorption Rate
Tijdsspanne: Baseline, Week 4, Week 12
|
Calcific deposit dimensions (long axis, short axis, area, and estimated volume) are quantified from ultrasound images using ImageJ software.
Percentage volume reduction from baseline is calculated.
Resorption is additionally categorized as complete, partial (>50%), partial (<50%), unchanged, or increased.
|
Baseline, Week 4, Week 12
|
|
Change from Baseline in Shoulder Range of Motion (ROM)
Tijdsspanne: Baseline, Week 4, Week 12
|
Active and passive range of motion measured in degrees with a goniometer for forward flexion, abduction, external rotation at 90° abduction, and internal rotation at 90° abduction.
|
Baseline, Week 4, Week 12
|
|
Tendon Structural Integrity on Ultrasound
Tijdsspanne: Baseline, Week 4, Week 12
|
Supraspinatus (or affected) tendon integrity graded on high-resolution ultrasound as intact, partial-thickness tear, or full-thickness tear.
Tendon thickness is recorded in millimeters.
|
Baseline, Week 4, Week 12
|
|
Patient Global Impression of Change (PGIC)
Tijdsspanne: Week 4, Week 12
|
Single-item 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the participant's overall perceived change since starting treatment.
|
Week 4, Week 12
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- N202604139
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .